EcoDrugPlus

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSLCRG00005010105
Gene Symbol: P2RY4
3 Cross references
165 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSLCRG00005018200
Gene Symbol: P2RY6
3 Cross references
182 Possible Orthologues:

Receptor (Tnfrsf)-Interacting Serine-Threonine Kinase 1, Like

Ensembl ID : ENSLCRG00005015975
Gene Symbol: RIPK1L
3 Cross references
197 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSLCRG00005008824
Gene Symbol: RAMP1
3 Cross references
191 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSLCRG00005004304
Gene Symbol: RAMP1
3 Cross references
184 Possible Orthologues:

Receptor-Type Tyrosine-Protein Phosphatase Beta

Ensembl ID : ENSLCRG00005012658
Gene Symbol: LOC104933190
2 Cross references
189 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSLCRG00005021963
Gene Symbol: RPTOR
3 Cross references
213 Possible Orthologues:

Renin

Ensembl ID : ENSLCRG00005022436
Gene Symbol: REN
3 Cross references
219 Possible Orthologues:

Ret Proto-Oncogene Receptor Tyrosine Kinase

Ensembl ID : ENSLCRG00005020306
Gene Symbol: RET
3 Cross references
205 Possible Orthologues:

Retinoic Acid Receptor Alpha

Ensembl ID : ENSLCRG00005014158
Gene Symbol: RARA
3 Cross references
331 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSLCRG00005008680
Gene Symbol: RARB
3 Cross references
393 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSLCRG00005003384
Gene Symbol: LOC104933084
2 Cross references
380 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).